Recent Updates
Recently added Catalysts
MGNX Negative Sentiment

MacroGenics (MGNX) Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with Substantial Losses Have the Opportunity to Lead the Action

Key Takeaway: Johnson Fistel, LLP has initiated a class action lawsuit on behalf of MacroGenics shareholders who experienced significant losses between March 7, 2024, and May 9, 2024. The lawsuit alleges that MacroGenics issued false and misleading statements while concealing adverse facts about early safety data from the TAMARACK Phase 2 clinical study. Shareholders are urged to act by September 24, 2024, to establish themselves as lead plaintiffs in the case. The allegations stemmed from the company's presentation of interim safety and efficacy data for its cancer treatment, which led to investor claims of misrepresentation.
Price reaction · baseline $4 (2024-08-01 close) · hit after-hours · 5 other MGNX headline(s) in the window, move may be shared
day 0 close
-4.2%
day 1
-10.5%
day 3 · peak
-15.5%

Market Sentiment Analysis

CONCERNS & RISKS

  • MacroGenics is facing a class action lawsuit due to allegedly false and misleading statements.
  • The lawsuit claims that the company hid material adverse facts regarding safety data from a clinical study.
  • Shareholders incurred substantial losses, implying significant investor dissatisfaction and potential financial repercussions for the company.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
5%
average across 4 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
Teplizumab
Phase 2 · Type 1 Diabetes Mellitus

Full Press Release Details

SAN DIEGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of MacroGenics, Inc. ("MacroGenics") (NASDAQ: MGNX).
If you incurred significant losses and want to act as the lead plaintiff in the MacroGenics class action lawsuit or determine if you are eligible to receive a potential recovery of your losses, please submit your details here: SUBMIT YOUR INFORMATION NOW
CLASS PERIOD: March 7, 2024 to May 9, 2024
LEAD PLAINTIFF DEADLINE: September 24, 2024
DOCKET #: 24-CV-02184 (D. Maryland)
ALLEGATIONS: False and/or misleading statements
Contact for More Information: James Baker, (619) 814-4471, jimb@johnsonfistel.com or fjohnson@johnsonfistel.com
According to the lawsuit, throughout the Class Period, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts related to early interim safety data results from the TAMARACK Phase 2 study. The claims arise on May 9, 2024, when MacroGenics presented interim updated safety and efficacy data for its cancer treatment study TAMARACK.
Investor Action Steps: Shareholders who incurred losses during the class period, have until September 24, 2024, to move the court to become a lead plaintiff in this action. A lead plaintiff will act on behalf of all other class members in directing the class-action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the class-action lawsuit. An investor's ability to share any potential future recovery of the class action lawsuit is not dependent upon serving as lead plaintiff.
About Johnson Fistel, LLP | Top Law Firm, Securities Fraud, Investors Rights:
Johnson Fistel, LLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. We also extend our services to foreign investors who have purchased on US exchanges. Stay updated with news on stock drops and learn how Johnson Fistel, LLP can help you recover your losses. For more information about the firm and its attorneys, please visit http://www.johnsonfistel.com.
Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, LLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.
501 W. Broadway, Suite 800, San Diego, CA 92101

Frequently Asked Questions

What is the MacroGenics class action lawsuit about?

The lawsuit alleges that MacroGenics made false statements about safety data results.

What is the deadline to become a lead plaintiff?

The deadline to become a lead plaintiff is September 24, 2024.

What is the class period for the lawsuit?

The class period runs from March 7, 2024, to May 9, 2024.

How can investors submit their information?

Investors can submit their information through the provided links in the announcement.

Who can act as the lead plaintiff?

Any shareholder who incurred losses during the class period can apply as lead plaintiff.

Last updated: Aug 2, 2024